NASDAQ
22.10.25 | 21:59
1,625 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.10. | ALX Oncology to present CD47 biomarker data for evorpacept at SITC | 1 | Investing.com | ||
| 03.10. | ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 12.09. | ALX Oncology appoints board member Klencke as interim CMO | 2 | Investing.com | ||
| 12.09. | ALX Oncology CMO Alan Sandler Resigns; Appoints Board Member Barbara Klencke As Interim CMO | 1 | RTTNews | ||
| 12.09. | ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | 212 | GlobeNewswire (Europe) | Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from... ► Artikel lesen | |
| 12.09. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | ALX Oncology doses first patient in phase 1 trial of EGFR cancer drug | 1 | Investing.com | ||
| 12.08. | ALX Oncology Q2 2025 slides: biomarker strategy shows promise as cash runway extends | 6 | Investing.com | ||
| 12.08. | ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 348 | GlobeNewswire (Europe) | - Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference... ► Artikel lesen | |
| 12.08. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | ALX Oncology Holdings' Earnings: A Preview | 3 | Benzinga.com | ||
| 05.08. | ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 | 1 | GlobeNewswire (USA) | ||
| 12.06. | ALX Oncology berichtet über Ergebnisse der Jahreshauptversammlung | 5 | Investing.com Deutsch | ||
| 12.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | H.C. Wainwright maintains ALX Oncology stock Buy rating | 4 | Investing.com | ||
| 20.05. | ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event | 183 | GlobeNewswire (Europe) | - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the... ► Artikel lesen | |
| 13.05. | ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 | 3 | GlobeNewswire (USA) | ||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.58 misses by $0.10 | 2 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | 418 | GlobeNewswire (Europe) | Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,730 | +0,06 % | Evotec Aktie: Gefährlich! Breakversuch scheint erneut zu scheitern | Wieder läuft die Evotec Aktie auf massive charttechnische Hindernisse an der 7-Euro-Marke an - und wieder könnte sie scheitern. Im Handel am Donnerstag erreichte die Biotech-Aktie auf XETRA in der Spitze... ► Artikel lesen | |
| MODERNA | 22,175 | -4,11 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
| NOVAVAX | 7,307 | +0,30 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 58,00 | +0,87 % | CRISPR THERAPEUTICS AG verharrt - jetzt wird's brenzlig! | ||
| INOVIO PHARMACEUTICALS | 1,980 | +3,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 22,300 | +5,34 % | Intellia (NTLA) Soars 13% to Fresh High | ||
| DEFENCE THERAPEUTICS | 0,540 | +6,30 % | Defence Therapeutics Inc.: Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025 | Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| EDITAS MEDICINE | 3,119 | +1,83 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 19,300 | -0,31 % | Sarepta-Aktie: Zurück zu altem Glanz? | Die Aktie von Sarepta Therapeutics steht wieder im Fokus der Biotech-Anleger. Nach einem starken Umsatzwachstum und hohen Erwartungen an neue Gentherapien fragen sich viele, ob das Papier seinen nächsten... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,340 | +0,78 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen | |
| EXELIXIS | 31,540 | +1,51 % | Exelixis shares dip on colorectal cancer data | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,542 | -2,48 % | PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| HALOZYME THERAPEUTICS | 56,80 | +0,21 % | Halozyme Rallies Almost 40% YTD: How Should You Play the Stock? | ||
| NEUROCRINE BIOSCIENCES | 123,00 | +0,90 % | Neurocrine Biosciences Announces Positive Data From Post-Hoc Analysis Of Tardive Dyskinesia Study | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Friday announced a new post-hoc analysis from the Phase 3, open-label KINECT 4 study, evaluating the long-term efficacy, safety and... ► Artikel lesen |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,625 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.